Бортезомиб (Bortezomib) is a medication applied in addressing certain cancers, specifically relevant within the therapeutic domain of hematologic malignancies. It is considered relevant as a proteasome inhibitor.

The primary therapeutic uses of Bortezomib involve managing specific blood cancers. Its primary approved indications include multiple myeloma and mantle cell lymphoma.

This treatment is commonly used across conditions presenting with acute episodes and is applied in clinical settings that involve acute or unstable symptom patterns. It supports patients during episodes of heightened discomfort and helps address symptom clusters that interfere with daily comfort. It is commonly used when short-term symptomatic assistance is needed.

“This supportive management may assist with maintaining functional stability when symptoms are more noticeable.”

Quick Fact: Supports ease of symptoms related to physical discomfort

Eligibility and Restrictions for Bortezomib Use

Bortezomib is approved for use exclusively in adult patients with specific hematologic malignancies. Its use is subject to formal contraindications and regulatory restrictions based on a patient's pre-existing health status and age.

Absolute Contraindications

The medicine must not be used in patients with a known hypersensitivity to bortezomib, boron, mannitol, or any excipients in the formulation. Use is also strictly prohibited in patients with severe hepatic impairment (per European labeling) and those with acute diffuse infiltrative pulmonary or pericardial disease. The medicine is never to be administered by the intrathecal route.

Conditional Use and Special Populations

Use is restricted for patients with preexisting severe peripheral neuropathy (Grade ge 2); treatment is permitted only after a careful risk-benefit assessment. Patients with moderate hepatic impairment require conditional use. Due to the risk of fetal harm, use is advised against in pregnant women. Females and males of reproductive potential must use effective contraception for specified durations during and following treatment. Safety and effectiveness are not established for pediatric patients (under 18 years).

Interactions with other medicines and products

Bortezomib is metabolized primarily by cytochrome P450 enzymes, particularly CYP3A4, and to a lesser extent, CYP2C19 and CYP1A2. This metabolic pathway is the basis for several important drug-drug interactions, which can alter the concentration of bortezomib in the body.

Interacting Product Category	Interaction Mechanism and Constraint
Strong CYP3A4 Inducers	Coadministration should be avoided as these agents can significantly decrease bortezomib exposure, potentially reducing its effectiveness.
Strong CYP3A4 Inhibitors	These agents can increase bortezomib exposure, raising the risk of toxicity. Patients must be closely monitored for signs of bortezomib toxicity, and a dose reduction may be necessary if coadministration is unavoidable.
Antihypertensives	Use caution; bortezomib is associated with hypotension, and concomitant use with antihypertensive medications may compound this effect.
Oral Antidiabetic Agents	Patients taking these agents require close monitoring of blood glucose levels, as bortezomib treatment has been linked to both hypoglycemia and hyperglycemia, potentially necessitating dose adjustment of the antidiabetic drug.

No specific medicinal products are consistently listed across all major regulatory labels; rather, the focus is on the identified substance classes and their predicted pharmacokinetic or pharmacodynamic effects. Healthcare providers should review all coadministered medications and products, including supplements, for potential interactions with the CYP enzyme system or for compounding toxicity risks.

How Bortezomib Works: Mechanism of Action

---

Targeted Inhibition of the Cell's Protein Recycling System

Bortezomib's mechanism begins with the reversible inhibition of the 26S proteasome complex, specifically targeting the beta5 subunit. This action disrupts the Ubiquitin-Proteasome Pathway (UPP), the cell's essential system for protein degradation, leading to a failure in protein homeostasis. This highly specific molecular interference initiates a cascade of significant cellular stress.

---

Cascade of Apoptosis and Survival Pathway Suppression

The blockade of the proteasome causes the rapid accumulation of pro-apoptotic factors (death signals) while simultaneously suppressing the pro-survival NF-kappaB signaling pathway. This dual-action cascade induces profound Endoplasmic Reticulum (ER) stress and leads the susceptible cells to undergo apoptosis (programmed cell death). This targeted cellular elimination results in the systemic reduction of the cell population.

Bortezomib is supplied as a lyophilized powder that requires specific preparation before clinical use. The medicine is administered via injection, with approval for both the intravenous (IV) route and the subcutaneous (SC) route. Administration by any other pathway is prohibited, and specific warnings are issued against intrathecal use.

The standard quantity administered is calculated precisely based on the patient’s Body Surface Area (BSA), with the typical initial dose set at 1.3 mg per square meter (m^2). A fundamental principle of the drug’s use is its cyclic and intermittent schedule. Dosing occurs on specific days within defined treatment cycles (e.g., twice weekly), and a minimum interval of 72 hours must be maintained between consecutive doses to adhere to the treatment regimen.

For administration, the powder must be reconstituted only with 0.9% Sodium Chloride (NaCl) solution. This preparation yields different concentrations for the approved routes; for example, 2.5 mg/mL for subcutaneous injection. The final administration must be supervised by a healthcare professional experienced with antineoplastic agents. Dose adjustments are utilized for specific patient groups, such as initiating treatment at a reduced dose of 0.7 mg/m^2 for individuals with moderate to severe hepatic impairment.

Research Evidence Overview of Studies for Bortezomib

This overview describes the types of clinical studies that have been conducted for Bortezomib and the aspects of disease management that researchers have examined, using language that is neutral and non-judgmental.

---

Evidence for Use in Multiple Myeloma (MM)

The body of research for Multiple Myeloma consists primarily of large Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews and Meta-analyses. These studies were conducted to compare treatment regimens against older standard treatments in large patient groups.

Researchers have explored the use of Bortezomib in patients who have been newly diagnosed with MM, as well as in patients whose disease has relapsed or become refractory (resistant) to previous treatments. Research compared treatment regimens containing Bortezomib against older standard treatments, such as high-dose dexamethasone alone. Findings describe patterns observed in the trials related to Overall Survival (OS) and Progression-Free Survival (PFS), which measures the time before the disease shows signs of progressing. Studies also monitored various response markers, such as the percentage of patients achieving a Complete Response (CR) and the level of Minimal Residual Disease (MRD) negativity. Data show patterns related to these outcomes when Bortezomib-containing regimens were studied alongside other comparison treatments.

Much of the high-level evidence available comes from studies where Bortezomib was used as one part of a multi-drug combination, rather than as a single therapy. This research provides context on how the combination regimens performed but offers limited insight into the medicine's use as a single agent in many key treatment settings. Additionally, while response markers are often measured in the short term, their correlation with long-term results is an area where evidence is still being developed.

---

Evidence for Use in Mantle Cell Lymphoma (MCL)

Research for Mantle Cell Lymphoma has involved both large Phase III comparative trials for previously untreated patients and earlier Phase II single-arm studies which were conducted prior to later comparative trials for relapsed disease.

A pivotal Phase III comparative trial evaluated a Bortezomib-containing regimen against the study's active control regimen, measuring outcomes such as Overall Survival and Progression-Free Survival. Findings from this trial describe patterns of measured Time to Progression that were compared against the study's control regimen. Other studies also explored the use of Bortezomib as a single agent or in different combinations for patients who have already received previous therapy. These studies monitored Overall Response Rates and the measured Duration of Response.

---

Long-Term Evidence and Durability of Response

Clinical research has explored outcomes over defined time intervals to understand the durability of any observed changes.

Research has explored long-term follow-up, with durations in key studies often ranging into several years, particularly for studies in Multiple Myeloma. Studies monitored metrics such as median Overall Survival and long-term Progression-Free Survival using these extended observations. This evidence contributes to understanding the long-term patterns observed in large patient groups. However, for some clinical settings and specific regimens, long-term outcomes are not fully established, and research is ongoing.

Key Studies & References

1. Bortezomib prolongs survival in MCL (Summary of LYM-3002 Trial)
2. A systematic review and meta-analysis of bortezomib subcutaneous versus intravenous administration in multiple myeloma and mantle cell lymphoma

Common questions about Бортезомиб (FAQ)

Q: What exactly is Bortezomib prescribed for?

According to official regulatory documents, Bortezomib is approved for the treatment of multiple myeloma and mantle cell lymphoma (MCL). The drug is used in adults and administered according to specific, approved treatment schedules for these conditions.

---

Q: Is Bortezomib considered chemotherapy or not?

Bortezomib is classified as a proteasome inhibitor, which is a type of targeted therapy. This classification means its mechanism involves specifically blocking a protein recycling system inside susceptible cells, rather than through the broader effects often associated with traditional chemotherapy.

---

Q: What are the most common side effects people notice from Bortezomib?

Official safety information indicates that among the very common side effects associated with Bortezomib are gastrointestinal issues, such as nausea, vomiting, diarrhea, and constipation. Other frequently reported effects include general fatigue or weakness.

---

Q: Is it true that Bortezomib causes numbness in the extremities (neuropathy)?

Yes, regulatory documents describe that peripheral neuropathy (a condition causing numbness, tingling, or pain, usually in the hands or feet) is a known risk associated with Bortezomib. This effect requires close medical monitoring and may necessitate adjusting the medicine's dose.

---

Q: Do I need to follow a special diet while taking Bortezomib?

Official instructions do not mandate a special restrictive diet during treatment. However, they note that some supplements, such as those containing green tea or ascorbic acid (Vitamin C), may interact with the medicine. The consideration of any potential dietary changes or the use of supplements is typically done in consultation with a healthcare provider.

---

Q: Can Bortezomib affect liver function?

Official documentation describes a risk of hepatotoxicity, which is toxic damage to the liver. For individuals with existing moderate or severe liver impairment, dose modification may be considered as part of the official prescribing information.

---

Q: How is it determined that Bortezomib is working in my case?

The effectiveness of Bortezomib is not typically measured by subjective feelings. Instead, it is monitored using regular blood tests and clinical examinations. These objective tests assess key markers like the level of disease response achieved and the time until any sign of disease progression.

---

Q: Can Bortezomib affect blood pressure?

Official documents indicate that treatment with Bortezomib is associated with a risk of developing hypotension (low blood pressure). Patients who are also taking medication for high blood pressure require special monitoring to manage this potential effect.

---

Q: Does taking Bortezomib affect the future possibility of having children?

Official information includes specific recommendations for contraception that apply to both male and female patients during treatment and for a set time afterward. This is due to the potential for the medicine to negatively affect a developing fetus.

---

Q: Is fatigue (weakness) during treatment related to the effect of Bortezomib?

Yes, asthenia—which is medically defined as general weakness or unusual fatigue—is listed in official documents as one of the very common side effects linked to the use of Bortezomib.

---

Q: What blood tests are needed regularly during treatment?

Official instructions require regular clinical blood counts to be performed during the course of treatment. This testing is essential to monitor key indicators, particularly the levels of leukocytes (white blood cells) and platelets in the blood.

---

Q: Is it true that Bortezomib can lower the platelet count?

Yes, the development of thrombocytopenia (a low platelet count) is an expected finding described in official documents. This hematologic side effect requires regular medical control and may lead to a temporary suspension of treatment if the count falls below a critical level.

---

Q: How long does Bortezomib stay in the body after administration?

According to pharmacokinetics data found in the official instructions, the average half-life of Bortezomib—the time it takes for half of the drug to be eliminated—is estimated to be approximately 40 to 193 hours after multiple administrations.

---

Q: What contraindications exist for taking Bortezomib?

Official contraindications include known hypersensitivity to the active substance, use during pregnancy or breastfeeding, and the presence of acute diffuse infiltrative pulmonary diseases or pericardial disease.

---

Q: How should Bortezomib be stored before use?

The lyophilized (freeze-dried) powder form of Bortezomib is specified to be stored at a temperature between 5 C and 30 C before it is prepared for administration.

---

Q: What is known about using Bortezomib in patients with kidney disease?

Official documentation indicates that patients with severe kidney (renal) function impairment should use Bortezomib with caution. This requires careful medical observation throughout the treatment course.

---

Q: What precautions should be taken at home during treatment?

Because of the documented risk of dizziness and hypotension (low blood pressure), precautions may include rising slowly from a sitting or lying position. The need to observe caution when moving, especially on stairs or when operating machinery, is noted in patient safety information.

---

Q: How does Bortezomib interact with antiviral drugs?

Bortezomib is known to influence the activity of certain Cytochrome P450 (CYP) enzymes in the body. Because many antiviral drugs are metabolized by this same system, official documents note that a potential interaction exists and requires professional assessment.

---

Q: Must Bortezomib be administered in a hospital setting?

Official requirements state that Bortezomib must be administered by a trained healthcare professional who has experience with antineoplastic agents. This typically takes place in a controlled medical setting, such as a hospital or specialized clinic.

---

Q: Can elderly people take Bortezomib?

Bortezomib is approved for use in adult patients. While general guidelines apply to all adults, official documents do not list age alone as a general exclusion or require a specific dose adjustment solely based on advanced age.

---

Q: Are there time limitations when Bortezomib treatment cannot be started?

Yes, certain severe health conditions act as temporary or permanent limitations. These include the presence of acute diffuse pulmonary diseases or pericardial disease. Additionally, treatment cannot begin if the patient has unresolved symptoms of severe toxicity from previous treatments.

---

Q: How long does a course of Bortezomib treatment usually last?

The total duration of treatment depends on the specific approved regimen being used. For example, in certain combination therapies, the total course may last for a defined number, such as up to nine 6-week cycles, as described in the official dosing schedules.

---

Q: How often are follow-up blood tests usually done after starting treatment?

Official documentation requires the regular performance of clinical blood counts throughout the treatment period. The exact frequency of these follow-up tests is determined by the treating physician based on the patient’s status and the treatment cycle.

---

Q: Can Bortezomib be used to treat other types of cancer besides those listed in the instructions?

According to official regulatory documentation, Bortezomib has approved indications only for the treatment of multiple myeloma and mantle cell lymphoma. The use of the drug for any other conditions falls outside the scope of the official prescribing instructions.

---

Q: Is there a difference in effectiveness between intravenous and subcutaneous administration?

Clinical studies reviewed by regulatory bodies indicate that when the medicine is administered via the subcutaneous (under the skin) route, the active substance is expected to be absorbed in the same way as with the intravenous route.

---

Q: Should I stop taking any vitamins or supplements during the course?

Official information includes a specific precaution regarding supplements. It warns that products containing ascorbic acid (Vitamin C) may potentially reduce the effectiveness of Bortezomib. Any supplements or vitamins should be reviewed with the medical team.

Storage and Disposal Requirements

Bortezomib (lyophilized powder) must be stored at controlled room temperature (20 C to 25 C). The unopened vial must be kept in its original package to ensure protection from light.

Once reconstituted, the solution has a time-limited stability. It should be used within 8 hours if kept at 25 C. Alternatively, it may be stored for up to 7 days under refrigeration (2 C to 8 C), but the total storage time must not exceed 7 days.

As a cytotoxic agent, bortezomib requires special handling. It must be kept out of the sight and reach of children. Any unused product or waste material must be discarded according to local requirements for cytotoxic agents and must not be disposed of in household waste or wastewater.